Amneal Pharmaceuticals LLC, a global supplier of generic pharmaceuticals, announced the launch of aripiprazole oral solution in 1 mg/ml strength, allowing prescribers to continue writing for the recently discontinued reference brand.

The Amneal generic - one of the first liquid forms on the market - is an AA-rated, therapeutic equivalent to the discontinued Abilify oral solution. It is now shipping in 150 ml (5 fl oz) bottles through wholesalers, distributors and directly to the trade.

“Healthcare providers can now continue prescribing a therapy they are comfortable with and in a form certain patients require,” explains Jim Luce, Amneal executive vice president of sales & marketing. “It’s a product that would otherwise be unavailable if not for the generic equivalent.”

Annual US sales of aripiprazole oral solution were $62.8 million as of June 2015, according to IMS Health.